MARKETS
S&P 5007,376.86+0.31%
NASDAQ 10026,989.99+1.35%
XBI152.21+2.57%
IBB213.63+1.73%
DOW 3051,285.73−0.46%
FTSE 10010,673.94−1.01%
Biotechnology Daily

Merck Tests Ohtuvayre for COPD Flare-Up Prevention

Merck’s global Ohtuvayre study will test whether the approved COPD maintenance drug can prevent flare-ups in patients already receiving standard treatment.

Trevor Hastings 2 min read
Doctor checking patient's blood pressure during medical consultation indoors.

Merck launched a Phase 3 trial expected to enroll 2,136 adults across 28 countries to evaluate Ohtuvayre for preventing COPD exacerbations alongside standard-of-care therapies.

Merck has launched a randomized Phase 3 trial testing whether Ohtuvayre can prevent chronic obstructive pulmonary disease (COPD) flare-ups in adults already receiving standard treatment. The study is expected to enroll 2,136 patients across 28 countries, targeting people with a history of exacerbations.

The trial gives the company a route to build evidence around exacerbation prevention for a medicine already approved for COPD maintenance treatment. Its central question is whether Ohtuvayre, also known as ensifentrine, can reduce moderate or severe episodes in patients whose treatment history includes those events.

Flare-up prevention is the main test

The primary endpoint—the main measure used to assess the trial—is the annualized rate of moderate or severe COPD exacerbations. An adjudication committee will determine which events qualify, according to MarketScreener.

That design places the frequency of flare-ups, rather than lung function alone, at the center of the study. Expressing events as an annualized rate allows researchers to evaluate how often qualifying episodes occur over time. The committee’s role is to assess those events against the study’s definitions.

Expressing events as an annualized rate allows researchers to evaluate how often qualifying episodes occur over time.

The patient population also defines the clinical question. Participants will be receiving standard-of-care therapies and must have a history of exacerbations. The trial therefore focuses on whether Ohtuvayre can address flare-ups in that treatment setting, rather than testing it only in patients without an exacerbation history.

Secondary measures include lung function, health-related quality of life, severe exacerbations and clinical tolerability. These will examine different dimensions of treatment: breathing performance, patients’ experience of their health, the most serious qualifying flare-ups and how well treatment is tolerated. Severe exacerbations will receive a separate assessment as well as being included in the main endpoint.

Building beyond the maintenance-treatment evidence

The Food and Drug Administration approved Ohtuvayre in June 2024 for COPD maintenance treatment, based on two trials. The inhaled medicine combines bronchodilator effects, which help open airways, with nonsteroidal anti-inflammatory activity.

The new study is not an initial test for that existing maintenance approval. It is a further late-stage evaluation focused specifically on exacerbation prevention. Launching the trial does not establish that benefit; the results will determine whether the study meets its prevention objective.

Merck intends to submit the findings to regulatory authorities worldwide, giving the international study a purpose beyond a single market. Separately, ensifentrine is being evaluated in a Phase 2 trial for non-cystic fibrosis bronchiectasis. That program addresses a different lung disease and remains distinct from the Phase 3 COPD prevention study.

Key facts

  • Trial sponsor: Merck (MRK)
  • Planned enrollment: 2,136 adults across 28 countries
  • Primary endpoint: Annualized rate of moderate or severe COPD exacerbations
  • Existing FDA approval: June 2024 for COPD maintenance treatment

Sources

Photo: Imad Clicks · Pexels Licence — source

Filed under Biotechnology Daily

More on Biotechnology Daily

See all →